Cleveland Clinic's 20th Annual ASH Review

http://www.clevelandclinicmeded.com/live/courses/ashreview/

 

Cleveland Clinic's 20th Annual ASH Review
A

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Novel Agent to the Backbone? How Can Next Generation BTKis Distinguish Themselves from Ibrutinib?

By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato
By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato
167 views
April 14, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Malignant Hematology
07:01
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of MDS: Clonal Hematopoiesis Increases Risk for Hema…

Feat. H. Carraway
26:41
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on MDS: Luspatercept Under FDA Review, Novel Oral HM…

Feat. H. Carraway
14:17
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Anemia in Myelofibrosis: Luspatercept Improvement…

Feat. S. Mukherjee
14:51
Cleveland Clinic's 20th Annual ASH Review

ASH 2019 Review on Treating Myelofibrosis in the Setting of Thromboc…

Feat. S. Mukherjee
06:37
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Limited Stage DLBCL: Can We Use PET Scan to Tailo…

Feat. B. Hill
08:38
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on R/R DLBCL: For Frail Unfit Patients, Addition of …

Feat. B. Hill
08:35
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on MCL: Can Anti-CD19 CAR-T Cell Therapy Be Used for…

Feat. B. Hill
06:19
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 an…

Feat. A. Mato
07:59
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Nov…

Feat. A. Mato
05:08
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Combinations or Sequences of Targeted Agents in C…

Feat. A. Mato
04:52
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow…

Feat. A. Mato
08:21
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Cov…

Feat. A. Mato
11:26
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review: Should High-risk Smoldering Myeloma Be Treated? Evi…

Feat. F. Anwer
05:49
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Newly Diagnosed Multiple Myeloma: VRD-Dara vs. VR…

Feat. F. Anwer
06:21
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Relapsed/Refractory: CAR T Cells - A New Frontier…

Feat. F. Anwer